GoodRx (NASDAQ:GDRX) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• GoodRx Holdings, Inc. experienced an unusual trading volume of over 5 million shares, increasing by 171% from the previous session, with its stock currently trading at $4.89.
• Multiple analyst ratings have been adjusted, with Goldman Sachs lowering its price target from $6.00 to $5.00, while UBS and Wells Fargo have also revised their targets, indicating a generally cautious outlook.
• The company reported a quarterly earnings miss, with an EPS of $0.09 against expectations of $0.10, contributing to ongoing concerns about its financial performance.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 5,003,278 shares were traded during mid-day trading, an increase of 171% from the previous session's volume of 1,849,519 shares.The stock last traded at $4.89 and had previously closed at $5.12.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. UBS Group lowered their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. The Goldman Sachs Group decreased their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Wells Fargo & Company lowered their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $5.80.

GoodRx Price Performance

The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. The stock's 50-day moving average price is $4.58 and its 200 day moving average price is $4.51. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 47.15, a price-to-earnings-growth ratio of 1.90 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The firm had revenue of $203.07 million for the quarter, compared to analyst estimates of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The firm's quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the business earned $0.08 earnings per share. Equities research analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.53% of the company's stock.

Institutional Investors Weigh In On GoodRx

Institutional investors and hedge funds have recently bought and sold shares of the business. 8 Knots Management LLC bought a new position in shares of GoodRx during the 1st quarter worth about $8,106,000. EVR Research LP raised its position in GoodRx by 243.3% in the first quarter. EVR Research LP now owns 1,300,000 shares of the company's stock worth $5,733,000 after purchasing an additional 921,337 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in GoodRx by 303.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock worth $4,936,000 after purchasing an additional 798,261 shares in the last quarter. Pathway Capital Management LP bought a new position in GoodRx during the second quarter worth about $2,906,000. Finally, Raymond James Financial Inc. acquired a new stake in GoodRx during the fourth quarter valued at approximately $2,500,000. Institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.